Enzo Biochem ( (ENZ) ) just unveiled an update.
On March 28, 2025, Enzo Biochem announced its decision to voluntarily delist its common stock from the New York Stock Exchange (NYSE) and move to the OTCQX Best Market. This strategic shift follows a notice from the NYSE regarding non-compliance with listing standards related to market capitalization, stockholder’s equity, and average closing stock price. The company plans for the delisting to be effective around April 17, 2025, with trading on OTCQX expected to begin on April 18, 2025. Enzo Biochem aims to ensure a smooth transition for shareholders, maintaining electronic trading without disruption and continuing to meet periodic reporting requirements under the Securities Exchange Act of 1934.
More about Enzo Biochem
Enzo Biochem, Inc. is a life sciences company with over 45 years of operation, primarily through its Life Sciences division, Enzo Life Sciences. The company specializes in labeling and detection technologies, offering a wide range of products including antibodies, genomic probes, assays, biochemicals, and proteins. These products are central to translational research and drug development in areas such as cell biology, genomics, assays, immunohistochemistry, and small molecule chemistry. Enzo Biochem monetizes its technology through global sales and licensing.
YTD Price Performance: -40.14%
Average Trading Volume: 131,019
Technical Sentiment Signal: Buy
Current Market Cap: $22.6M
Find detailed analytics on ENZ stock on TipRanks’ Stock Analysis page.